Prospective Bladder Cancer Infrastructure (ProBCI)
- Conditions
- Bladder Cancer
- Registration Number
- NCT04503577
- Lead Sponsor
- Prospective Bladder Cancer Infrastructure Foundation
- Brief Summary
Prospective nation-wide cohort of high-risk non-muscle-invasive, muscle-invasive and metastatic bladder cancer in the Netherlands
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 3600
- Bladder cancer
- Any stage except Ta
- 18 years or older
- Written informed consent
- No exclusion criteria
Note: participation in ProBCI does not exclude the patient from participation in other studies.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival 10 years Alive/death/emigrated
- Secondary Outcome Measures
Name Time Method Cancer-specific health-related quality of life 2 years QLQ-C30 (Quality of Life Questionnaire-Cancer)
Progression-free survival 10 yeas Progression/no progression
Health-related quality of life 2 years EQ-5D (EuroQol-Five Dimensions)
Recurrence-free survival 10 yeas Recurrence/no recurrence
Trial Locations
- Locations (23)
Jeroen Bosch Hospital
🇳🇱's-Hertogenbosch, Netherlands
ZGT
🇳🇱Almelo, Netherlands
Meander Medical Center
🇳🇱Amersfoort, Netherlands
Amsterdam UMC, location VUMC
🇳🇱Amsterdam, Netherlands
Rijnstate
🇳🇱Arnhem, Netherlands
Amphia Ziekenhuis
🇳🇱Breda, Netherlands
Albert Schweitzer Hospital
🇳🇱Dordrecht, Netherlands
Ziekenhuis Gelderse Vallei
🇳🇱Ede, Netherlands
Treant Hospital
🇳🇱Emmen, Netherlands
University Medical Center Groningen
🇳🇱Groningen, Netherlands
Scroll for more (13 remaining)Jeroen Bosch Hospital🇳🇱's-Hertogenbosch, Netherlands